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Gallstone disease (GD) is a major health problem in devel-oped societies, affecting ≤15% of the general popula-
tion.1 Although many risk factors for gallstone formation are 
not modifiable, obesity, diabetes mellitus, metabolic syn-
drome, rapid weight loss, and a sedentary lifestyle are risk 
factors for GD that can be changed.1 Moreover, the chronic 
use of some drugs (eg, octreotide, thiazide diuretics, and some 
oral contraceptives) may also increase the risk of developing 
GD.1 In contrast, long-term statin use seems to prevent gall-
stone formation, possibly by decreasing biliary cholesterol 
secretion and saturation and inhibition of cholesterol crystal 
formation.1,2 The rising pandemic of obesity and the metabolic 
syndrome is likely to lead to an increase in the prevalence of 
gallstones in many parts of the world in the foreseeable future.
See accompanying article on page 2232
Interestingly, in this issue of the journal, Lv et al3 examined 
the association between GD (as diagnosed by a standardized 
questionnaire) and the risk of incident ischemic heart disease 
(IHD) among 199 292 men and 288 081 women aged 30−79 
years in the China Kadoorie Biobank study. Participants with 
a previous history of cancer, IHD, and stroke at baseline were 
excluded from the study. At baseline, 5.8% of 487 373 adult 
participants reported the presence of GD (men 3.7%; women 
7.3%). During a median follow-up period of 7.2 years, there 
were 10 245 incident cases of IHD (≈90% nonfatal) in men 
and 14 714 (≈95% nonfatal) in women. The authors found 
that GD was associated with an increased incidence of IHD 
events (ie, a combined end point inclusive of fatal and nonfa-
tal events), independently of multiple cardiovascular risk fac-
tors. As compared with those subjects without GD at baseline, 
the multivariate-adjusted hazard ratios for IHD were, respec-
tively, 1.11 (95% confidence interval 1.02−1.22) for men with 
GD and 1.27 (95% confidence interval 1.20−1.34) for women 
with GD. Interestingly, the association between GD and inci-
dent IHD was found to be stronger in women (than in men) 
and in nonhypertensive compared with hypertensive individu-
als. In contrast, the association between GD and incident IHD 
was similar across subgroups stratified by age, smoking sta-
tus, alcohol consumption, physical activity level, and presence 
of obesity or diabetes mellitus.3
The relationship between GD and risk of IHD has been 
debated for many years,4–6 with some recent cross-sectional 
and prospective studies showing an independent association 
between GD and IHD7,8 and between GD and cardiovascular 
mortality and morbidity.9–12 That said, the findings described by 
Lv et al3 are timely and clinically relevant. The study extends 
previously published data and shows that GD independently 
predicts incident IHD in a prospective cohort of over 0.5 mil-
lion adults from 10 geographically diverse areas across China. 
The major limitations of this study were the self-reported diag-
nosis of GD and the lack of any information about insulin resis-
tance, dyslipidemia, use of lipid-lowering drugs, nonalcoholic 
fatty liver disease (NAFLD), and variation in gut microbiota. 
However, despite these limitations, this is the largest prospec-
tive cohort study to date examining the association between 
GD and risk of IHD. In addition, the follow-up duration of the 
study was relatively long, the authors have adjusted for many 
important potential confounders, and the results were consis-
tent across clinically relevant subgroups.
The reasons for the increase in IHD risk related to GD 
remain largely unexplained. GD and IHD are 2 common dis-
eases that share multiple cardiometabolic risk factors, and it 
is now important to understand how GD is linked to IHD. 
Cholesterol is the main component of most gallstones and 
also atheromatous plaques. Whether GD and IHD are found 
more frequently together because they share common risk 
factors or whether the pathogenesis of both is causally linked 
is uncertain. Gallstone formation requires dysregulation of 
biliary lipid secretion, biliary cholesterol supersaturation, and 
also gallbladder hypomotility and the presence of pronucleat-
ing factors, such as a nidus of infection.1 Alterations in hepatic 
processing of the lipid globule and availability of cholesterol 
for both very low–density lipoprotein and bile acid secretion 
could be a shared pathway for both GD and IHD. Altered bile 
acid metabolism associated with GD may also influence sev-
eral nuclear receptors that are involved in the regulation of 
lipogenesis and insulin sensitivity, such as peroxisome pro-
liferator–activated receptors, liver X receptors, farnesoid X 
receptor, and hepatocyte nuclear factor 4α.13
An association between GD and NAFLD has been shown 
in recent cross-sectional studies,14 and mounting evidence 
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suggests that NAFLD is an emerging risk factor for IHD and 
plays a key role in the development of hepatic insulin resis-
tance and atherogenic dyslipidemia.15,16 Preliminary evidence 
also suggests that GD is associated with more severe liver 
damage in NAFLD patients.17 Additionally, some population-
based studies also reveal a significant association between 
NAFLD and cholecystectomy, but no association between 
NAFLD and gallstones,18,19 suggesting that cholecystectomy 
might not be innocuous and may contribute to NAFLD devel-
opment and progression. Increasing evidence is now sug-
gesting a role for dysbiosis of the intestinal microbiota in 
obesity, diabetes mellitus, and maybe also NAFLD and IHD.20 
Dysbiosis can increase the proportion of gram-negative bac-
teria in the portal circulation and also increase the production 
of lithogenic bile acids, both of which could increase the risk 
of GD. In the Figure, we have attempted to summarize the 
putative underlying mechanisms by which dysbiosis might 
mediate a link between GD, obesity, NAFLD, and IHD. A 
better understanding of these mechanisms would enable us to 
better tailor a treatment for both patients with GD and those 
with IHD.
In summary, although it is not proven that there is a causal 
link between GD and IHD, it is important that clinicians are 
aware of the significant association between GD and risk 
of IHD. For patients with GD, we suggest that a multidisci-
plinary approach based on a careful evaluation of coexisting 
cardiometabolic risk factors and monitoring for IHD and liver 
complications is now warranted. It is possible to speculate 
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Figure. Intestinal dysbiosis: mediating a link between gallbladder disease, obesity, nonalcoholic fatty liver disease, and ischemic heart 
disease (IHD)? Dysbiosis (an imbalance) of the intestinal microbiota may increase the proportion of gram-negative pathogenic bacteria 
and lipopolysaccharide (LPS) in the portal circulation, and dysbiosis also influences the enterohepatic bile circulation. Altered circulation 
of bile acids (BAs) induced by dysbiosis may increase the production of lithogenic BAs, increasing the potential for gallstone formation by 
affecting the amount of cholesterol remaining in solution in the bile. Normally the highly efficient enterohepatic circulation of BAs ensures 
that the majority of synthesized BAs are recycled to the liver, with only 1% to 2% of BAs in the bile being converted into secondary BAs 
(eg, deoxycholic acid and lithocholic acid) by bacterial 7α-dehydroxylation in the terminal ileum and colon. The presence of bacterial 
infection in the biliary tract because of the increase in gut permeability can also provide the nidus for gallstone formation. Dysbiosis also 
affects both energy harvesting from highly caloric foods (with consequences for development of obesity) and the generation of short-
chain fatty acids (SCFAs; eg, acetate, propionate, and butyrate) produced from bacterial fermentation of carbohydrate. In normal physiol-
ogy, adequate production of SCFA lowers the colonic pH and inhibits the proliferation of harmful gram-negative bacteria. Alternation of 
production of SCFAs may also influence hepatic lipogenesis and gluconeogenesis that can both be affected in nonalcoholic fatty liver 
disease (NAFLD). With development of NAFLD, there may also be increased secretion of very low–density lipoprotein (VLDL), decreased 
high-density lipoprotein cholesterol (HDL-C), and increased small, dense low-density lipoprotein cholesterol (LDL-C) particles (ie, ath-
erogenic dyslipidemia) together with increased production of proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and 
interleukin-6 (IL-6). Dysbiosis may also influence intestinal dietary choline metabolism with the production of potentially toxic metabolites, 
such as trimethylamine (TMA). TMA is oxidized in the liver to TMA oxide (TMAO), which has been shown in atheroma-prone mouse stud-
ies to be harmful to coronary arteries, perhaps increasing risk of IHD. Dysbiosis also decreases production of fasting-induced adipose 
factor (FIAF) that is an inhibitor of lipoprotein lipase, thus leading to increased adipose tissue triglyceride accumulation. Similarly, dysbio-
sis-induced decreases in SCFAs may lead to a decrease in GPR43-mediated suppression of insulin signaling and consequent increase in 
adipose tissue triglyceride accumulation. Finally, alteration of the diet can also influence the function of neuroendocrine cells, such as L 
cells in the small intestine, that produce peptides, such as glucagon-like peptide-1 and 2 (GLP-1 and GLP-2) and peptide YY (PYY), that 
may act centrally to influence satiety. GLP-1 is also a powerful incretin influencing secretion of insulin from pancreatic beta cells, thereby 
modifying glucose metabolism.
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that long-term statin therapy in patients with GD might exert 
a beneficial effect not only on IHD prevention but also on the 
cholesterol gallstone formation, consequently decreasing the 
need for cholestectomy.2 However, it is likely that new ran-
domized clinical trials are needed to test the effect of statins 
on GD to address this issue.
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